We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Interferon-β stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
- Authors
Kraus, J.; Voigt, K.; Schuller, A. M.; Scholz, M.; Kim, K. S.; Schilling, M.; Schäbitz, W. R.; Oschmann, P.; Engelhardt, B.
- Abstract
Background Blood-brain barrier (BBB) breakdown is an early event in the pathogenesis of multiple sclerosis (MS). In a previous study we have found a direct stabilization of barrier characteristics after treatment of bovine brain capillary endothelial cells (BCECs) with human recombinant interferon-β-1a (IFN-β-1a) in an in vitro BBB model. In the present study we examined the effect of human recombinant IFN-β-1a on the barrier properties of BCECs derived from four different species including humans to predict treatment efficacy of IFN-β-1a in MS patients. Methods We used primary bovine and porcine BCECs, as well as human and murine BCEC cell lines. We investigated the influence of human recombinant IFN-β-1a on the paracellular permeability for 3H-inulin and 14C-sucrose across monolayers of bovine, human, and murine BCECs. In addition, the transendothelial electrical resistance (TEER) was determined in in vitro systems applying porcine and murine BCECS. Results We found a stabilizing effect on the barrier characteristics of BCECs after pretreatment with IFN-β-1a in all applied in vitro models: addition of IFN-β-1a resulted in a significant decrease of the paracellular permeability across monolayers of human, bovine, and murine BCECs. Furthermore, the TEER was significantly increased after pretreatment of porcine and murine BCECs with IFN-β-1a. Conclusion Our data suggest that BBB stabilization by IFN-β-1a may contribute to its beneficial effects in the treatment of MS. A human in vitro BBB model might be useful as bioassay for testing the treatment efficacy of drugs in MS.
- Subjects
BLOOD-brain barrier; BRAIN blood-vessels; ANTINEOPLASTIC agents; MULTIPLE sclerosis; MYELIN sheath diseases; DRUG efficacy; BIOLOGICAL assay
- Publication
Multiple Sclerosis (13524585), 2008, Vol 14, Issue 6, p843
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/1352458508088940